SEP-363856 hydrochloride

SEP-363856 hydrochloride (SEP-856 hydrochloride), an orally active and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 hydrochloride (SEP-856 hydrochloride) has the potential for the study of schizophrenia In Vitro SEP-856 (10 μM) shows >50% inhibition of specific binding at α 2A , α 2B , D 2 , 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 2A , 5-HT 2B , 5-HT 2C , and 5-HT 7 receptors. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SEP-856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs . SEP-856 (0.3, 1 and 10 mg/kg, orally once) significantly reduces PCP-induced hyperactivity . Oral SEP-856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Acute treatment with phencyclidine (PCP), which induces robust hyperactivity in rodents . Dosage: 0.3, 1 and 3 mg/kg. Administration: Orally once. Result: Resulted in a dose-dependent inhibition of PCP-induced hyperactivity responses in C57Bl/6J mice (1-way ANOVA F (5, 59) = 18.96, p IC50& Target:TAAR1 0.140 μM (EC 50 ) 5-HT 1A Receptor 2.3 μM (EC 50 ) 5-HT 1B Receptor 15.6 μM (EC 50 ) 5-HT 1D Receptor 0.262 μM (EC 50 ) 5-HT 2A Receptor >10 μM (EC 50 ) 5-HT 2C Receptor 30 μM (EC 50 ) 5-HT 7 Receptor 6.7 μM (EC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet